IMMU Immunomedics Inc.

17.2
-0.26  -1%
Previous Close 17.46
Open 17.4
Price To Book 132.31
Market Cap 3,325,689,608
Shares 193,354,047
Volume 1,067,958
Short Ratio
Av. Daily Volume 2,367,110
Stock charts supplied by TradingView

NewsSee all news

  1. Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late November/Early

  2. Immunomedics to Present at the 2019 Cantor Global Healthcare Conference

    MORRIS PLAINS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  3. Immunomedics Provides Corporate Update

    Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include Discussing

  4. Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  5. Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (OTC:MGTI), First American Financial Corporation (NYSE:FAF),

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated.
SACITUZUMAB GOVITECAN
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.
SACITUZUMAB GOVITECAN
Urothelial cancer
NDA to be refiled late-November / early December, 2019.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus
Phase 3 trial has been initiated.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-02
HR+/HER2- metastatic breast cancer
Phase 1/2 interim data presented at ESMO September 2019 noted 29% ORR.
SACITUZUMAB GOVITECAN - TROPHY U-01
Urothelial cancer
Phase 1/2 trial underway.
Lucitanib with Rubraca (SEASTAR)
Ovarian cancer
Phase 2 trial has been initiated.
SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-03
Solid tumors
Phase 2 data due 2H 2020.
SACTUZUMAB GOVITECAN (IMMU-132) - ASCENT
Cancer - metastatic triple-negative breast cancer

Latest News

  1. Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late November/Early

  2. Immunomedics to Present at the 2019 Cantor Global Healthcare Conference

    MORRIS PLAINS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  3. Immunomedics Provides Corporate Update

    Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy Future Steps Include Discussing

  4. Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress

    MORRIS PLAINS, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  5. Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (OTC:MGTI), First American Financial Corporation (NYSE:FAF),

  6. Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

    MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today

  7. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQGM: IMMU) filed a class action complaint against the company for alleged violations of the Securities

  8. Immunomedics to Participate in Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today